Inflammation and Immunosuppression Flashcards
Omalizumab
mAb against IgE, used to treat dermatographic urticarial and allergic asthma
Binds to Cepsilon3 region of IgE (heavy chain) so prevents IgE binding to FcepsilonRI
Built on an IgG framework so doesn’t activate FcepsilonRI itself
Injection every 2-4w
Sodium cromoglyate
Reduces Ca2+ influx into mast cells, prevents degranulation. In eye drops for hayfever and used for mastocytosis, and occasionally asthma
Salbutamol
Short-acting beta2 adrenoceptor agonist, used as needed in treatment of asthma
Maximum effect in 30min
Duration of action 3-5hrs
Formoterol
Long-acting beta2 adrenoceptor agonist, prophylactic use in the treatment of asthma
Duration of action 8-12 hours
Long lipophilic tail enables it to be incorporated into the plasma membrane, which acts as a drug reservoir, and also the long tail binds to an extra binding site on the beta2 aidrenoceptor itself
Theophylline
PDE inhibitor producing increased cAMP, used prophylactically in treatment of asthma/COPD
Mepyramine
1st generation H1 receptor antagonist, crosses BBB causes drowsiness, used topically to treat insect bites.
Terfenadine
2nd gen H1 antagonist, inhibited hERG causing long QT syndrome and so no longer used. Prodrug metabolised by Cytochrome p450 3A4 to fexofenadine (the active compound).
Fexofenadine
3rd gen anti-histamine. Non-drowsy, no cardiac side effects. Used to treat hayfever and urticaria.
Loratidine
3rd gen anti-histamine, non-drowsy, used to treat hayfever and urticaria.
Adrenaline
Used to treat anaphylactic shock
Hydrocortisone
Corticosteroid used as anti-inflammatory. Short t1/2 <24h
Inhibits neutrophil degranulation
Imatinib
RTK inhibitor used in treatment of human mastocytosis. Ineffective in treatment of people with common D816V c-kit mutation.
Oclacitinib
Treatment of atopic dermatitis in dogs. Inhibits JAK, greatest specificity for JAK1, which is common to many signalling pathways associated with allergic skin diseases - so lowers proinflammatory signalling.
Proglumide
CCK2 receptor antagonist that produces an inhibition of histamine release from ECL cells
Cimetidine
H2 receptor antagonist, inhibits cytochrome p450, replaced by ranitidine
Ranitidine
H2 receptor antagonist, used in treatment of peptic ulcers
Omeprazole
PPI used in treatment of peptic ulcers.
Clarithromycin
Macrolide antibiotic used to eradicate H. pylori
Misoprostol
Synthetic PGE1 analogue acts to decrease ECL histamine release in treating peptic ulcers.
Arthrotec
Combination of misoprostol and diclofenac, used in chronic treatment of rheumatoid arthritis to prevent peptic ulcer formation. Misoprostol acts as a prophylactic agent against NSAID-induced ulceration.
Diclofenac
NSAID used in treating chronic inflammation
Ecallantide
Kallikrein inhibitor used in the treatment of HAE.
Tanezumab
Anti-NGF antibody, in clinical trials for treating OA
Bufexamac
LTA4 hydrolase inhibitor, can be used as an anti-inflammatory agent
Montelukast
CysLT1 receptor antagonist, used in treatment of asthma
Ibuprofen
Non-selective COX inhibitor, used as analgaesic, anti-pyretic and anti-inflammatory.
Etoricoxib
COX2 selective inhibitor, reserved for chronic inflammation in patients thought not to have substantial cardiovascular risk
Aspirin
Irreversible NSAID (acetylates ser530) that is used additionally to lower the risk of platelet aggregation.
Naproxen
NSAID
Paracetamol
Analgesic/anti-pyretic COX inhibitor that doesn’t cause the anti-inflammatory actions of classical NSAIDs.
Acetylcysteine
Increases hepatic glutathione production following paracetamol OD
Phenylbutazone
NSAID used mainly in horses, many side effects in humans
Robenacoxib
COX2 selective inhibitor used in cats and dogs
Firocoxib
COX2 selective inhibitor used in dogs and horses
Ondansetron
5-HT3 receptor antagonist used to prevent and treat vomiting
Cyclizine
H1 receptor antagonist used as an antiemetic
Scopolamine
Non-specific muscarinic receptor antagonist, acts via M1 to inhibit nausea and vomiting
Domperidone
D2 receptor antagonist, anti-emetic. More peripherally selective than metoclopramide, so produces acute dystonia less frequently
Metoclopramide
D2 receptor antagonist, used to treat nausea/vomiting. Can cause acute dystonia
Sumatriptan
5-HT1B/D/F agonist used in treatment of migraine
Side effect of peripheral vascular vasoconstriction, so contraindicated in coronary disease
Poorly absorbed when taken orally
Doesn’t cross BBB
Short duration of action
Available in nasal spray and subcutaneous injection
Lasmiditan
5-HT1F agonist being developed for potential use in treatment of migraine
Naratriptan
5-HT1B/D/F agonist used in treatment of migraine
Longer duration of action
Can cross BBB
Fewer cardiac side effects
Propanolol
Non-selective beta-adrenoceptor antagonist used prophylactically in migraine
Amytripyline
Antidepressant used, at lower concs, as a migraine preventative (inhibition of VGSC and inhibition of NET/SERT), also sedative and dry mouth due to anticholinergic action
Topirimate
Anti-epileptic, also used prophylactically in migraine, acts on numerous ion channels including inhibiting VGSC and facilitating GABAA
Side effects tingling in hands and feet
Pizotifen
serotonin antagonist that blocks 5-HT2A and 2B receptors, used in migraine prevention
Botulinum toxin A
Disrupts synaptic vesicle release by cleaving SNAREs, used prophylactically in migraine
Erunumab
mAb against CGRP, in development for use against migraine
Prednisolone
Corticosteroid - binds to glucocorticoid receptors, used as anti-inflammatory and immunosuppression.
Betamethasone
Corticosteroid, used as anti-inflammatory
Dexamethasone
Corticosteroid, anti-inflammatory, binds to glucocorticoid receptors, used as an anti-inflammatory and in immunosuppression. Long lasting t 1/2 > 48h
Indacaterol
Ultra long acting beta2 adrenoceptor agonist, used in the treatment of COPDb
Beclomethasone
Corticosteroid, used as anti-inflammatory, commonly as an inhalable corticosteroid
Prophylactic treatment of asthma
Ipratropium
Non-selective muscarinic antagonist, used in treatment of asthma and COPD
Fluticasone
Corticosteroid, can be used as anti-inflammatory in cats/horses
Clenbutarol
Long acting beta2 adrenoceptor agonist used in treatment of recurrent airway obstruction in horses
Tiotropium
Long acting muscarinic antagonist used in the treatment of COPD
Roflumilast
Selective PDEIV inhibitor approved in treatment of COPD
Methotrexate
DHFR inhibitor used as a DMARD in rheumatoid arthritis
Sulfasalazine
DMARD
Administered orally, broken down by colonic bacteria to sulfapyridine and 5-amino salicylic acid
The acid scavenges ROS from nphils
Daily tablet
Don’t see therapeutic benefit for 3 months+
GI disturbances, skin rash, bone marrow suppression, hepatotoxicity, tears and contact lenses stained yellow, urine orange
Hydroxychloroquine
DMARD and anti-lupus drug
Weak base so accumulates in cytoplasmic acidic vesicles
Reduces Ag presentation by mphages and neutrophil ROS generation
Side effects ocular toxicity, GI upset, skin reactions, seizures, myopathy and psychiatric disturbance
Azathioprine
Prodrug for 6-mercaptopurine. Inhibits DNA synthesis in cells lacking a nucleotide salvage pathway (B and T cells) - used as an immunosuppressant
DMARD
Side effects: bone marrow suppression, hepatotoxicity, GI upset
Leflunomide
Inhibits dihydroorotate dehydrogenase and thus pyrimidine synthesis.
Main effect on rapidly dividing cells like B and T cells
used in RA
Adverse effects GI disturbance, bone marrow suppression, hepatotoxicity
Penicillamine
DMARD, may act by decreasing IL1 synthesis and collagen maturation
Rarely used for RA now
Has chelator properties so also sued following heavy metal poisoning and in Wilson’s disease
Side effects rashes, GI disturbance, bone marrow suppression, disturbances in taste
Auranofin
DMARD, unknown mechanism. Appears to inhibit IL1 and TNFalpha induction.
Side effects skin rashes, mouth ulcers, chrysiasis after long-term use (permanent grey/blue skin colouration)
Now rarely used as RA inhibitors
Etanercept
Fusion product of the soluble TNFalpha receptor and IgG1, used in RA
Infliximab
Chimeric anti-TNFalpha mAb, used in RA
Adalimumab
Human anti-TNFalpha mAb, used in RA
Tocilizumab
Anti IL6 receptor mAb, used in RA
Rituximab
Anti CD20 mAb, causes B cell destruction, used in RA
Abatacept
synthetic fusion protein of the costimulkatiory CTLA4 with an IgFc fragment. Interferes with T cell activation, so used in treatment of RA.
Anakira
Recombinant IL-1 receptor antagonist used in RA
Capsaicin
TRPV1 agonist used in osteoarthritis
IRAP
IL1 receptor antagonist protein, used to treat osteoarthritis in horses
Insulin lispro
Fast acting insulin used to treat DM
Analogue swapping of lys and pro towards C terminus of B chain
Reduces dimer and hexamer formation so larger amounts of active monomeric insulin are available after injection
Onset 5-15mins, duration 4-6h
Insulin actrapid
Short acting insulin, used to treat DM
Onset 30-60 mins, duration 8-10h
NPH insulin
Intermediate acting insulin used to treat DM
Neutral protamine hagedorn
Suspension of protamine polypeptide and insulin that forms relatively insoluble crystals, thus slowing absorption
Onset 2-4h, duration 12-18h
Glargine
Long acting insulin used to treat DM
AA changes to A and B chains change isoelectric point to more neutral
When injected subcutaneously, forms a microprecipitate of stable hexamers and higher aggregates, which retard and prolong absorption
Onset 2-4h, duration 20-24h
Metformin
Numerous beneficial effects in treating Type 2 DM, many involving activation of AMPK, the cellular energy sensor.
Decreased hepatic gluconeogenesis
Increased glucose uptake skeletal muscle
Decreased intestinal carbohydrate absorption
Decreased circulating levels VLDL and LDL
Decrease appetite
side effects: NOT hypoglycaemia: GI disturbances, lactic acidosis as inhibits hepatic lactate uptake, so alcoholics or people with renal dysfunction shouldn’t take metformin
Glibenclamide
Sulfonylurea used to inhibit KATP to enhance insulin release. Used in treatment of Type 2 DM.
Bind to SUR1 subunit of KATP channels, causes closure, triggering dep, Ca2+ influx and insulin release
Significant conversion to active products in the liver before urinary excretions, so action potentiated in people with renal inefficiency
Can cross placenta so contraindicated in pregnancy and breastfeeding
Possible interaction with SUR2A in heart
Glipizide
Sulfonylurea used to inhibit KATP to enhance insulin release. Used in treatment of Type 2 DM.
Bind to SUR1 subunit of KATP channels, causes closure, triggering dep, Ca2+ influx and insulin release
Mainly metabolised in liver to inactive products and excreted in urine
Can cross placenta so contraindicated in pregnancy and breastfeeding
Repaglinide
Meglitinide compound, inhibits KATP enhancing insulin release, used to treat type 2 DM.
Also binds to SUR1
Lower risk of hypoglycaemia
Faster onset and offset kinetics than sulfonylureas
Exenatide
Mimics effect of GLP-1 but longer acting, to stimulate insulin release/inhibit glucagon release. Used to treat type 2 DM.
Sitagliptin
Inhibits DPP-4 and thus slows GLP1/GIP breakdown. Used to treat Type 2 DM.
Dapagliflozin
SGLT2 inhibitor (the kidney PCT one), used to treat Type 2 DM.
Pioglitazone
Activates PPARgamma TF in adipose tissue/liver/muscle Increased lipogenesis Glucose/fatty acid uptake Increased transcription GLUT4 Treatment type 2 DM
Acarbose
alpha-glucosidase inhibitor used in treatment of type 2 DM.
Slows the breakdown of starch/disaccharides into glucose in the GI tract
Reduce the amount of glucose entering the bloodstream
Belimumab
Anti-BLyS mAb used in SLE.
Mycophenolic acid
Inhibits IMPDH, crucial for guanosine synthesis, used as an immunosuppressant
Cyclophosphamide
Alkylating agent, kills dividing T and B cells, used as an immunosuppressive
Prodrug for phosphoromide mustard
Ciclosporin A
Drug binds to cyclophilin CpN which forms a CsA-CpN complex
CsA-CpN complex binds to and inhibits CaN
Prevents NF-AT dephosphorylation, retained in cytoplasm
IL2 depressed
Used as immunosuppressant suppressing rejection of transplanted organs
Tacrolimus
Macrolide antibiotic
Binds to FKBP, binds to and inhibits CaN, retains NF-AT in cytoplasm, inhibits IL2 transcription, can be used as an immunosuppressant in organ transplantation
Basiliximab
mAb against CD25 alpha subunit of the IL2 receptor, used as an immunosuppressant
IL2R found on activated T and B cells
Belatacept
Fusion protein of CTLA4 (which binds to CD80/86 and sends an inhibitory signal to the T cell) and IgG1.
Used as immunosuppressant
Sirolimus
Binds to FKBP, inhibits mTOR
mTOR is a ser/thr kinase involved in cell cycle progression and protein synthesis
Results in decreased T cell activation and proliferation and a decreased immune response
decreased T cell activation/proliferation, used as immunosuppressant
Coating of coronary stents to prevent restenosis
= Rapamycin
Muromonab-CD3
Anti-CD3 mAb, used to reduce acute transplant rejection
Murine
Alemtuzumab
mAb, binds to CD52 (on mature lymphocytes but not the stem cells they came from), used in treating chronic lymphocytic leukaemia, cutaneous T-cell lymphoma and T-cell lymphoma
Catumaxomab
Bifunctional mAb, anti-epCAM on cancer cells and anti-CD3 on T cells, used to treat acites in cancer patients
Trastuzumab
anti-HER2 mAb, used to treat HER2 positive breast cancers
Disruption of HER2 signalling and targeting tumour cells for ADCC
Trastuzumab emtansine (T-DM1)
anti-HER2 mAb coupled to antimicrotubule compound maytansine (DM1), used to treat HER2 positive breast cancers
Binding of T-DM1 to HER2 –> internalisation, lysosomal degradation –> release of DM1- -> bind to tubulin and prevent polymerisation causing cytotoxicity
Also just trastuzumab actions: disruption of HER2 signalling and targeting tumour cells for ADCC
What are the four signs of inflammation?
Redness
Swelling
Heat
Pain
What causes inflammation?
- Noxious stimulation
- Bacterial/viral/fungal infection
- Autoimmune reactions
What is the triple response of Lewis?
- Flush - due to local release of vasodilator substances such as histamine
- Flare - 30-60s post inflammation redness spreads to surrounding area because of neurogenic inflammation
- Wheal - localised swelling due to histamine causing increased vascular permeability
Define neurogenic inflammation
Stimulated branch of a sensory nerve will send an action potential to the branching point, which travels both orthodromically to the spinal cord –> pain and antidromically —> collateral branches to result in the release of CGRP and substance P –> directly cause vasodilation, and substance P is also a potent activator of mast cell degranulation –> local production of histamine –> vasodilationa nd increased vascular permeability
Why does increased vascular permeability cause swelling?
- Plasma leaks into extracellular space
2. Plasma has higher tonicity compared to ECF so pulls water out of cells
What receptor mediates inflammation?
H1
What is dermatographic urticarial?
Condition where the triple response is exaggerated
Idiopathic
Treat with H1 receptor antagonists, and omalizumab MAb against IgE, decreases mast cell activation
Discuss the toxin alpha haemolysin
UPEC
Ca2+ oscillations in cells –> induce synthesis of proinflammatory cytokines IL6 IL8
Lyses host cells
Activate innate and adaptive immune system
Give a theory of why autoimmune reactions occur
Pathogen with an Ag similar to a protein expressed by the host triggers an immune attack, initially against the pathogen, but then continues to attack host tissues after the pathogen has been destroyed
What does TLR stim by PAMPS cause sentinel cells to release?
Proinflammatory mediators:
Prostaglandins PGE2/PGI2 - vasodil
Histamine - vasodil vascular perm
TNFalpha, IL-1 - produce further cytokines, vasc perm and expression of adhesion molecules on the intimal surface of postcapillary venules
What are the 4 proteolytic systems in exudate?
- Coagulation
- Fibrinolysis
- Kinin
- Complement
What does bradykinin do?
Vasodilator Increases vascular permeability Spasmogen Causes pain Generates eicosanoids Stim endothelial NO synthesis
What does C3a do?
Releases histamine from mast cells
Spasmogen
What does C5a do?
Chemotaxin + activates WBCs
Activates phagocytic cells
Releases histamine from mast cells
What triggers C3 –> C3b?
- Classical/Lectin pathway C1 C4 C2
- Alternative pathway Spontaneous
- Thrombin
- Plasmin
- Neutral proteases from phagocytic cells
What activates factor XII?
Contacting negatively charged substances like collagen
What makes up the MAC?
1 x C5b, C6, C7, C8
12-18 x C9
How do neutrophils get to a bacterium in the extracellular space?
- Capture Sialyl Lewis X and PSGL1 to P selectin
- Tight adhesion LFA-1 to ICAM-1
- Extravasation PECAM1 + integrins
- Chemotaxis C5a fMLF
How is histamine made?
Histidine - histidine decarboxylase
4 cells: mast cells, basophils, ECL in gut and histaminergic neurons in the brain
How is histamine packaged in basophils?
Acidic granules with HMW heparin called macroheparin
How is histamine released?
Ca2+ i increase leads to exocytosis
- C3a/C5a –>Gi –> betagamma –> PLCbeta –> IP3 –> increase Ca2+i
- Substance P –> Mas-related gene X2 MrgX2 receptors –> Gq –> PLCbeta –> IP3 –> increase Ca2+i
- IgE cross linking with FCepsilonRI due to allergens –> phos of LAT adaptor protein linker for activation of t cells –> PLCgamma –> IP3 –> Ca2+ release